Insmed (INSM) News

Express News | Insmed Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BreakingsSep 4 19:00

Insmed To Present Five Abstracts At ERS Congress 2026, Including Late-Breaking Phase 3b ENCORE Data On ARIKAYCE In Newly Diagnosed MAC Lung Disease On September 6

Insmed To Present Five Abstracts At ERS Congress 2026, Including Late-Breaking Phase 3b ENCORE Data On ARIKAYCE In Newly Diagnosed MAC Lung Disease On September 6

BenzingaSep 3 19:11

If You Invested $1000 In Insmed Stock 10 Years Ago, You Would Have This Much Today

Insmed (NASDAQ:INSM) has outperformed the market over the past 10 years by 10.74% on an annualized basis producing an average annual return of 24.29%. Currently, Insmed has a market capitalization

BenzingaAug 28 23:30

RBC Capital Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $195

RBC Capital analyst Leonid Timashev maintains $Insmed(INSM.US)$ with a buy rating, and maintains the target price at $195.According to TipRanks data, the analyst has a success rate of 64.8% and a

Futu NewsAug 27 10:31

RBC Capital Reaffirms Their Buy Rating on Insmed (INSM)

TipRanksAug 27 09:45

Health Care Roundup: Market Talk

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 1259 ET - Moderna's finding that the mRNA-based vaccine it

WSJAug 26 04:50

Morgan Stanley Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $218

Morgan Stanley analyst Maxwell Skor maintains $Insmed(INSM.US)$ with a buy rating, and maintains the target price at $218.According to TipRanks data, the analyst has a success rate of 72.6% and a

Futu NewsAug 25 19:34

Mizuho Adjusts Price Target on Insmed to $195 From $192, Keeps Outperform Rating

Insmed (INSM) has an average rating of buy and mean price target of $200.18, according to analysts polled by FactSet.

MT NewswiresAug 25 17:24

Insmed Stock Seen by Mizuho as Undervalued -- Market Talk

1811 ET [Dow Jones]--Insmed's shares aren't being given a fair shake by traders, who may be using their positions as "a source of funds" given a broader run-up in biotechnology stocks, Mizuho

WSJAug 25 06:12

Mizuho Securities Maintains Insmed(INSM.US) With Buy Rating, Raises Target Price to $195

Mizuho Securities analyst Graig Suvannavejh maintains $Insmed(INSM.US)$ with a buy rating, and adjusts the target price from $192 to $195.According to TipRanks data, the analyst has a success rate

Futu NewsAug 25 04:32

Insmed Earns Buy Rating as Brinsupri Japan Approval Drives Stronger Global Outlook and Price Target Raised to $195

TipRanksAug 25 03:55

Insmed's Lung Disease Drug Gets Approved in Japan

Insmed (INSM) said Monday Japan approved its drug, Brinsupri, to treat non-cystic fibrosis bronchiectasis in adults and children aged 12 and older.The company said the approval was based on a phase 3

MT NewswiresAug 24 19:54

Guggenheim Sticks to Their Buy Rating for Vicore Pharma Holding AB (6Y4)

TipRanksAug 24 19:15

Insiders At Insmed Sold US$36m In Stock, Alluding To Potential Weakness

Many Insmed Incorporated (NASDAQ:INSM) insiders ditched their stock over the past year, which may be of interest to the company's shareholders. When evaluating insider transactions, knowing

Simply Wall StAug 23 20:11

Biotech Is Booming, But These 2 Stocks Missed the Memo

Biotech stocks are having one of their best stretches in years. The iShares Biotechnology ETF (NASDAQ:IBB) jumped nearly 5% Wednesday and pushed to new all-time highs, according to data from

BenzingaAug 21 00:03

US Stock Market Close | US Treasury intervenes to support long-term bonds, lifting all three major indices; Moderna surges, igniting a rally in the biopharmaceutical sector, with Merck & Co up over 12% and the S&P Biotechnology ETF rising nearly 6%; Bitco

The S&P 500 closed up 0.21% at 7,707.98, the Nasdaq Composite rose 0.16% to 26,331.09, and the Dow Jones Industrial Average gained 0.22% to 53,463.05, ending a three-day losing streak for all three major indices. Moderna surged 176.97% to hit a record high, while Merck & Co jumped 13%, leading the healthcare sector's gains in the S&P; meanwhile, semiconductor and AI momentum stocks suffered heavy losses, with chip ETFs falling a cumulative 7.7% over two days.

wallstreetcnAug 20 07:02

The "Holy Grail" of cancer treatment? Moderna's Phase III trial for its melanoma mRNA vaccine succeeds, sending shares up nearly 180%

Moderna and Merck & Co announced on Wednesday that their jointly developed personalized mRNA cancer vaccine achieved positive results in a large Phase III clinical trial. This marks the first successful Phase III trial for mRNA technology in cancer treatment and represents a major breakthrough in personalized immunotherapy in the history of oncology. Shares of Merck & Co rose nearly 13%, leading gains in the Dow Jones Industrial Average.

wallstreetcnAug 20 06:24

Insmed Insider Sold Shares Worth $637,650, According to a Recent SEC Filing

Melvin Sharoky, Director, on August 17, 2026, sold 5,000 shares in Insmed (INSM) for $637,650. Following the Form 4 filing with the SEC, Sharoky has control over a total of 267,901 common shares of

MT NewswiresAug 20 04:20

BMO Capital Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $192

BMO Capital analyst Conor MacKay maintains $Insmed(INSM.US)$ with a buy rating, and maintains the target price at $192.According to TipRanks data, the analyst has a success rate of 40.0% and a total

Futu NewsAug 18 20:34

Analysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Insmed (INSM)

TipRanksAug 18 19:40